Wyeth to use seasoned part-timers to support reduced rep force

Share this article:
Wyeth will use inside, part-time sales representatives to complement its full-time sales force, which is being reduced by about 25 percent to 30 percent, the company said.
Adding the part-timers will result in a net sales force reduction of about 15 percent, said Bernard Poussot, Wyeth executive vice president.
"We think we've found a way to cut the waste, the wasted energies of sales reps calling on doctors [and finding it difficult to] get quality time with physicians," he said.
By trimming its full-time ranks, Wyeth aims to reduce the number of reps targeting the same doctor. Sales personnel will be assigned to detail multiple products.
As for part-timers, Wyeth has deployed them in its consumer division for the past few years. As reported in MM&M, the drug maker's began piloting them in its pharmaceuticals division in July and said it will fully implement them by year's end (MM&M, July 2005).
Part-timers will fulfill "a different type of mission" in servicing physicians, Poussot said. The reps will drop off samples and sales materials to doctors "without necessarily having to see them."
Poussot noted that so far the pilot has elicited a pool of candidates that is more experienced than applicants for traditional, full-time roles. "We have people who have done the job for many years and, at this stage of their lives, they want to be on a part-time basis. They are very experienced part-time individuals."
The changes are expected to result in more "quality" sales time with doctors for regular reps, more flexibility and higher productivity levels for the company, Poussot said.
"The reactions to our approach have been very good within the company and outside," he added. "Physicians like the concept of reducing the number of reps on key brands."
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...